Budesonide rectal foam for ulcerative colitis in ages 5–17
Part of Digestive system clinical trials.
This study tests a rectal foam (a foam you insert into the rectum) containing budesonide, a steroid that reduces inflammation, for children and teens aged 5–17 with mild to moderate ulcerative colitis in the lower colon. It aims to find the best dose that is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 5 and 17 years old.
- You must have ulcerative colitis that affects only the lower part of the colon and rectum (not the whole colon).
- Your ulcerative colitis must be mild or moderate, not severe.
- If you are already taking oral 5-ASA medicine for ulcerative colitis, the dose must have been the same for at least 6 weeks.
- You must not have Crohn's disease or another type of inflammatory bowel disease.
- You must not have had surgery on your intestines, except for appendix or hernia surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether budesonide extended-release tablets are safe and effective for improving symptoms in children ages 5–17 with active, mild to moderate ulcerative colitis. It also measures how the medicine moves through the body.
This trial tests whether butyrate can help children and teens with mild-to-moderate ulcerative colitis (a long-term bowel inflammation condition). You may be able to join if your symptoms fit the study level and you haven’t recently started other specific ulcerative colitis treatments right before the study begins.
This trial tests a new treatment for people with ulcerative colitis (UC) whose disease is active despite taking only mesalamine or sulfasalazine. It aims to find a therapy that can reduce inflammation and improve symptoms.
This trial tests a specific probiotic (a type of beneficial bacteria) to see if it can help people with mild to moderate ulcerative colitis by improving the balance of gut microbes. It may be an option if you have not used many advanced treatments before.
This trial studies whether transferring healthy stool bacteria into the gut (fecal microbiota transplantation, or FMT) can improve symptoms in children with ulcerative colitis. It may help by changing gut bacteria, especially for children who are newly diagnosed or who didn’t respond to standard treatments.
This trial tests a budesonide liquid that targets inflammation in the esophagus, stomach, and duodenum (upper digestive tract) in children with Crohn's disease. It aims to see if this treatment can reduce inflammation in those areas without strong side effects.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.